• Acute Myeloid Leukemia

Dr. Kebriaei received her B.S. degree from Yale University in 1993, and her M.D. degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000. She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia (ALL), and she has led the development of the transplant program in ALL. She is also interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, and investigating the use of mesenchymal stromal cells for the therapy of graft versus host disease. Finally, she has been involved in the development of the CARTOX committee, a cross-disciplinary committee to oversee the safe administration of cellular therapy treatments. Dr. Kebriaei is actively involved in current phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.